CVRx (CVRX) to Release Earnings on Tuesday

CVRx (NASDAQ:CVRX) is projected to release its Q4 2025 results before the market opens on Tuesday, February 3rd. Analysts expect CVRx to post earnings of ($0.42) per share for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, February 4, 2026 at 12:00 AM ET.

CVRx (NASDAQ:CVRX) last announced its earnings results on Wednesday, November 5th. The company reported ($0.49) EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.01. The company had revenue of $14.69 million for the quarter, compared to analysts’ expectations of $14.16 million. CVRx had a negative return on equity of 84.45% and a negative net margin of 92.95%. On average, analysts expect CVRx to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

CVRx Price Performance

NASDAQ CVRX opened at $7.33 on Tuesday. The business’s fifty day moving average is $7.96 and its 200 day moving average is $8.22. CVRx has a fifty-two week low of $4.30 and a fifty-two week high of $17.78. The company has a debt-to-equity ratio of 1.03, a quick ratio of 8.60 and a current ratio of 9.62. The company has a market capitalization of $192.12 million, a PE ratio of -3.63 and a beta of 1.31.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Cantor Fitzgerald lifted their price objective on CVRx from $11.00 to $13.00 and gave the company an “overweight” rating in a research report on Thursday, November 6th. Weiss Ratings restated a “sell (d-)” rating on shares of CVRx in a research note on Monday, December 29th. Finally, Canaccord Genuity Group lifted their price target on shares of CVRx from $9.00 to $11.00 and gave the company a “buy” rating in a report on Thursday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $11.40.

Insider Buying and Selling

In other CVRx news, major shareholder & Johnson Johnson sold 52,332 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $10.21, for a total value of $534,309.72. Following the completion of the transaction, the insider directly owned 4,051,098 shares in the company, valued at $41,361,710.58. This represents a 1.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last 90 days, insiders sold 56,232 shares of company stock valued at $573,442. 18.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On CVRx

Several institutional investors and hedge funds have recently modified their holdings of the stock. Bank of America Corp DE lifted its holdings in shares of CVRx by 102.6% in the third quarter. Bank of America Corp DE now owns 180,425 shares of the company’s stock worth $1,456,000 after buying an additional 91,376 shares in the last quarter. Vanguard Group Inc. increased its holdings in CVRx by 1.2% in the 3rd quarter. Vanguard Group Inc. now owns 1,090,226 shares of the company’s stock valued at $8,798,000 after acquiring an additional 12,948 shares during the last quarter. Balyasny Asset Management L.P. increased its holdings in CVRx by 65.5% in the 2nd quarter. Balyasny Asset Management L.P. now owns 674,685 shares of the company’s stock valued at $3,967,000 after acquiring an additional 267,063 shares during the last quarter. Marshall Wace LLP lifted its stake in CVRx by 238.1% in the 2nd quarter. Marshall Wace LLP now owns 350,080 shares of the company’s stock worth $2,058,000 after purchasing an additional 246,548 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of CVRx by 6.4% during the 2nd quarter. Geode Capital Management LLC now owns 382,437 shares of the company’s stock valued at $2,249,000 after purchasing an additional 23,079 shares during the last quarter. Institutional investors own 75.27% of the company’s stock.

CVRx Company Profile

CVRx, Inc is a clinical-stage medical device company focused on developing a neuromodulation platform therapy for patients with cardiovascular disease. The company’s flagship product, the Barostim™ system, delivers targeted electrical stimulation to the carotid baroreceptors with the goal of modulating the body’s natural blood pressure control mechanisms. This minimally invasive, implantable therapy is designed to address unmet needs in individuals suffering from hypertension and heart failure.

The Barostim system is currently being evaluated in multiple clinical trials, including studies in resistant hypertension and advanced heart failure.